Takeda said it has discontinued efforts to develop a drug combining its Actos diabetes drug and TAK-536 angiotensin receptor blocker (ARB) after it found difficulty in mixing the two.
It will not elaborate on the difficulties encountered, a Takeda spokesman said.
'Takeda has reached the conclusion that it is optimal to prioritize projects other than (the fixed dose combination product of Actos and TAK-536) in order to provide novel treatment options (for diabetes and cardiovascular diseases) as early as possible,' it said in a statement.
Source
Hmmmm!
No comments:
Post a Comment